Bio-Rad Launches Three StarBright Red Dyes and Expands Range of Antibody Markers Conjugated to StarBright Violet Dyes to Enhance Immunology Research

Bio-Rad’s Range of StarBright Dyes Conjugated to Highly Validated Antibodies Now Totals 32 Dyes, Providing Greater Choice and Flexibility for Conventional and Full-Spectrum Flow Cytometry in Immunology Research.

HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of three new StarBright™ Red Dyes — StarBright Red 715, 775, and 815 — and an expansion of its StarBright Violet Dye series with 29 additional highly validated antibodies conjugated to StarBright Violet 570, 515, 440, 670, 790, and 475 Dyes. Now totaling 32 dyes spanning multiple lasers, Bio-Rad’s range of StarBright Dyes expands translational and immunological research capabilities by providing greater choice and flexibility in conventional and full-spectrum multicolor flow cytometry panels. 

Bio-Rad’s range of StarBright Dyes, proprietary fluorescent nanoparticles conjugated to flow-validated antibodies against key immunological targets, offer researchers exceptional brightness with narrow excitation and emission profiles for precise resolution. Joining StarBright Red 670, the first StarBright Red Dye, launched last year, StarBright Red 715, 775, and 815 are excitable by the 640 nm laser and are brighter or as bright as other current 640 nm excitable comparison dyes that emit at a similar wavelength. With minimal background compared with tandems containing cyanine dyes, the StarBright Red Dyes are also stable and can be fixed in formalin or alcohol-based fixatives. 

StarBright Dyes are compatible with most experimental protocols and flow cytometers, including the Bio-Rad ZE5 Cell Analyzer, without the need for special buffers. Minimal lot-to-lot variation helps to ensure reproducible and consistent staining, and the dyes are resistant to photobleaching with no loss of signal in fixation.

Expanding the range of human and mouse targets and introducing dog, cow, and pig targets, the additional 29 antibody markers conjugated to StarBright Violet 570, 515, 440, 670, 790, and 475 Dyes will soon be available on all StarBright Dyes

“The Bio-Rad StarBright Dye portfolio, now totaling 32 dyes across the 355, 405, 488, 561, and 640 nm lasers, is the most comprehensive series of dyes designed specifically for conventional and full-spectrum flow cytometry, and offers superior alternatives to existing dyes,” said Hilary Mavor, Marketing Director, Life Science Group, Bio-Rad. “By continuing to expand our existing portfolio of antibody markers, including new human, mouse, dog, cow, and pig targets, we can offer our customers greater choice and flexibility when building multicolor panels in conventional and full-spectrum flow cytometry.”  

To learn more about Bio-Rad StarBright Dyes and StarBright Red Dyes, visit and

BIO-RAD and STARBRIGHT are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.  

About Bio-Rad  

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 8,000 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit

Forward-Looking Statements

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.


< | >